§ — Researched for · Tissue repair & injury recovery
Several peptides are being researched for tendon, ligament, muscle and gut-lining repair — most prominently BPC-157 and TB-500. As of September 2026, none is approved by the FDA for any use, and the human evidence for injury recovery is limited to small, short studies that FDA reviewers described as underpowered.
Reviewed September 2026 · Sources: FDA, EMA
02 — What is being studied
The research field is regenerative signalling: whether short peptide sequences can influence how tendon, ligament, muscle and intestinal lining rebuild after damage. Endpoints under study in animals are collagen organisation at the tendon-to-bone junction, capillary formation in healing tissue, and the integrity of the gut mucosal barrier after chemical or ischaemic injury. Those models are where nearly all of the published data sits.
In humans the picture is much thinner. Trials that exist are small, short and mostly aimed at gastrointestinal indications rather than at sports injury, which is the use that dominates online discussion. Nothing published tracks return-to-sport timelines, re-injury rates or structural healing on imaging against a control group. The distance between the animal literature and any clinical endpoint is the central fact of this field as of September 2026.
03 — The table
| Peptide | Researched for | Evidence | Regulatory status | As of |
|---|---|---|---|---|
| GHK-Cu | Skin aging, wound healing, hair growth, gene expression modulation. | B | Not an approved drug. Widely used as a cosmetic ingredient in topical products, which is regulated as a cosmetic, not a drug. Injectable use is not approved and its compounding status must be verified. | 2026-09-06 |
| BPC-157 | Tendon, ligament and muscle healing; gastrointestinal mucosal protection; ulcerative colitis (the indication FDA reviewed in 2026). | C | Not FDA-approved for any use. Placed in 503A Category 2 in 2023 over immunogenicity and impurity concerns; removed from Category 2 on April 15, 2026 after nomination withdrawal — which is not a listing in Category 1. Reviewed by the Pharmacy Compounding Advisory Committee on July 23, 2026; FDA proposed not to add it to the 503A Bulks List. Compounding remains outside the 503A exemption until rulemaking concludes. | 2026-09-06 |
| LL-37 | Chronic wound infection, biofilm disruption, venous leg ulcers. | C | Not FDA-approved. Previously withdrawn from review; FDA has announced a further PCAC meeting before the end of February 2027 to reconsider it for the 503A Bulks List. | 2026-09-06 |
| TB-500 | Wound healing, cardiac tissue repair after injury, corneal healing. | C | Not FDA-approved. Removed from 503A Category 2 in April 2026; reviewed by PCAC on July 23, 2026 with FDA proposing not to list. Not eligible for 503A compounding. | 2026-09-06 |
04 — Per peptide
Regulatory status · United States · as of September 2026
Not an approved drug. Widely used as a cosmetic ingredient in topical products, which is regulated as a cosmetic, not a drug. Injectable use is not approved and its compounding status must be verified.
Source: FDA 503A Bulks List · PCAC meeting records · verified September 2026
Researched forSkin aging, wound healing, hair growth, gene expression modulation.
Full profile: GHK-Cu →Regulatory status · United States · as of September 2026
Not FDA-approved for any use. Placed in 503A Category 2 in 2023 over immunogenicity and impurity concerns; removed from Category 2 on April 15, 2026 after nomination withdrawal — which is not a listing in Category 1. Reviewed by the Pharmacy Compounding Advisory Committee on July 23, 2026; FDA proposed not to add it to the 503A Bulks List. Compounding remains outside the 503A exemption until rulemaking concludes.
Source: FDA 503A Bulks List · PCAC meeting records · verified September 2026
Researched forTendon, ligament and muscle healing; gastrointestinal mucosal protection; ulcerative colitis (the indication FDA reviewed in 2026).
Full profile: BPC-157 →Regulatory status · United States · as of September 2026
Not FDA-approved. Previously withdrawn from review; FDA has announced a further PCAC meeting before the end of February 2027 to reconsider it for the 503A Bulks List.
Source: FDA 503A Bulks List · PCAC meeting records · verified September 2026
Researched forChronic wound infection, biofilm disruption, venous leg ulcers.
Full profile: LL-37 →Regulatory status · United States · as of September 2026
Not FDA-approved. Removed from 503A Category 2 in April 2026; reviewed by PCAC on July 23, 2026 with FDA proposing not to list. Not eligible for 503A compounding.
Source: FDA 503A Bulks List · PCAC meeting records · verified September 2026
Researched forWound healing, cardiac tissue repair after injury, corneal healing.
Full profile: TB-500 →05 — What the data does not show
Faster return to sport, systemic anti-inflammatory benefit and long-term safety have not been demonstrated in humans for any peptide in this group.
06 — Questions for your physician
Listing in the registry is not an endorsement of any substance or protocol, and it is not a statement that a treatment is approved.
Reviewed September 2026 · Sources: FDA, EMA
This page reports on the state of research and regulation for orientation. It is not medical advice, not a recommendation for or against any substance, and not an offer. Regulatory status changes; the date shown is the date of our last verification. Discuss any treatment with a licensed physician.